Discussion Our findings demonstrate that GLP-1 receptor agonist-based therapeutics significantly disrupt the interoceptive stimulus effects of alcohol, highlighting a potential therapeutic mechanism through which these medications may reduce alcohol consumption and motivation
ncbi.nlm.nih.gov/books/NBK557646/ #16
The SLR underpinning this study did not identify any formal sequencing studies or direct comparisons of SGLT2is versus GLP-1 RAs [16]
After 24 weeks of treatment, significant reductions in neuropathy symptom and disability scores and in neurophysiological parameters were seen in both groups, with no difference between the two drugs safety-wise
This guide breaks down what retatrutide actually is, how it differs from existing weight loss medications, what the clinical trial data shows, the risks nobody wants to talk about openly, and what you should actually do if youre considering weight loss treatment right now
The Clinical Biochemist